Abstract
Abstract
Background
Global developmental delay or intellectual disability usually accompanies various genetic disorders as a part of the syndrome, which may include seizures, autism spectrum disorder and multiple congenital abnormalities. Next-generation sequencing (NGS) techniques have improved the identification of pathogenic variants and genes related to developmental delay. This study aimed to evaluate the yield of whole exome sequencing (WES) and neurodevelopmental disorder gene panel sequencing in a pediatric cohort from Ukraine. Additionally, the study computationally predicted the effect of variants of uncertain significance (VUS) based on recently published genetic data from the country’s healthy population.
Methods
The study retrospectively analyzed WES or gene panel sequencing findings of 417 children with global developmental delay, intellectual disability, and/or other symptoms. Variants of uncertain significance were annotated using CADD-Phred and SIFT prediction scores, and their frequency in the healthy population of Ukraine was estimated.
Results
A definitive molecular diagnosis was established in 66 (15.8%) of the individuals. WES diagnosed 22 out of 37 cases (59.4%), while the neurodevelopmental gene panel identified 44 definitive diagnoses among the 380 tested patients (12.1%). Non-diagnostic findings (VUS and carrier) were reported in 350 (83.2%) individuals. The most frequently diagnosed conditions were developmental and epileptic encephalopathies associated with severe epilepsy and GDD/ID (associated genes ARX, CDKL5, STXBP1, KCNQ2, SCN2A, KCNT1, KCNA2). Additionally, we annotated 221 VUS classified as potentially damaging, AD or X-linked, potentially increasing the diagnostic yield by 30%, but 18 of these variants were present in the healthy population of Ukraine.
Conclusions
This is the first comprehensive study on genetic causes of GDD/ID conducted in Ukraine. This study provides the first comprehensive investigation of the genetic causes of GDD/ID in Ukraine. It presents a substantial dataset of diagnosed genetic conditions associated with GDD/ID. The results support the utilization of NGS gene panels and WES as first-line diagnostic tools for GDD/ID cases, particularly in resource-limited settings. A comprehensive approach to resolving VUS, including computational effect prediction, population frequency analysis, and phenotype assessment, can aid in further reclassification of deleterious VUS and guide further testing in families.
Funder
Oakland University
Joint Operational Programme Romania-Ukraine, through the European Neighborhood Instrument
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Shevell MI, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, et al. Practice parameter: evaluation of the child with global developmental delay [RETIRED]: report of the Quality standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurol AAN Enterprises. 2003;60:367–80.
2. Srour M, Shevell M. Genetics and the investigation of developmental delay/intellectual disability. Arch Dis Child BMJ Publishing Group Ltd. 2014;99:386–9.
3. Miclea D, Peca L, Cuzmici Z, Pop IV. Genetic testing in patients with global developmental delay/intellectual disabilities. A review. Clujul Medical. Volume 88. Romania: Universty of Medicine and Pharmacy of Cluj-Napoca; 2015. p. 288.
4. Lincoln SE, Truty R, Lin C-F, Zook JM, Paul J, Ramey VH, et al. A rigorous interlaboratory examination of the need to confirm next-generation sequencing–detected variants with an orthogonal method in clinical genetic testing. J Mol Diagnostics Elsevier. 2019;21:318–29.
5. Annual reports. [Internet]. Annual reports.Center of Medical statistics of Ministry of Health Care. 2021. Available from: http://medstat.gov.ua/ukr/reports.html.